


Cheap MC, Patent secured today, volume in with buyers stepping up. Re-rating. BIOSHARE mentioned that PAB could be takeover before clinical trials due to interest in this technology. As always DYOR
At time of posting MXR has a 14MC with 87 SOI. -Recently raised cash for drilling in a prospective regions -It has high profile investors such as Tolga on board who has a successful track record of getting on winners. See BGL as a recent Example -Drilling catalyst due soon -Hot gold sector with nearology play What makes this stonk interesting is that there is a...
EOS has just deferred its revenue. We have just received two announcements this week confirming both a new product line and resumption of trade in backlogs. People selling are short term, chasing yield. IMO fundamentals are very strong given, rising Asian region tensions and the desire of Australian Government to have local defensive suppliers. We will see more...
IP Studies underway for drill targets Cash on hand is $2million AUD at 5B Share Issue 58.63 million
As attached. This stock is way overbought. has shown in the past to sell down heavily when it has been overbought.
SPQ has commenced drilling operations on prospective drill targets for Gold. Low MC, large upside.
See chart. Macro events are in play. Fundamentals in place, Chart to confirm. Trade at your own risk
See chart. Short interest 12%. From highs massive retrace. Sellers exhausted
Although there is a risk of following the channel and filling the second gap, I am hoping that it will bounce from here. A second parcel could be entered at the second gap or next higher higher.
See chart. Defence industry exposure. Management confirmed dividends first payment still likely this year.
Bub has consolidated over the period from highs. New financial year, with selling drying up. Buyside building. Watch to resume uptrend with news due from recent agreements from Large supermarkets. Expect increased sales of product locally.
Target 30c, waiting for sellers to exit. Before resuming upward trend to test resistances
After very strong growth and fomo buying Sar is now due for a cool off to the mean. Should expect weaker prices from here, with a buy zone between 4 to 4.50 range
THC a fully vertically integrate THC business with real assets, will look to supply Australian and international markets with CBD oils and other products. Recent acquition of tetra health provides a channel for distribution with its manufacturing ability it should also be a cost leader within its sector. THC has strong prospects fundamentally to test resistance...
See chart. Ascending nicely higher lows. Will break through resistance